ClinicalTrials.gg
CompletedNCT00489853CODEXUpdated Aug 30, 2012Results posted

Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD

A Phase 4 interventional study of budesonide/formoterol Turbuhaler 320/9µg and formoterol Turbuhaler 9µg in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 9 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-08-30.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
97th of 194
137 · median 137
Started
2007
with 8 others
Phase 4
19 of 284
2 open now
Registered
23rd of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 97th largest by enrollment of the 194 interventional ones that give a count, is one of 9 that started in 2007, is one of 19 in phase 4, and was the 23rd registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect on exercise tolerance, lung function and symptoms after treatment with Symbicort, Oxis or placebo in patients with severe chronic obstructive pulmonary disease.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >=40 years of age
  • diagnosed with symptoms >= 2 years
  • pre-bronchodilatory \<=50% of PN

Exclusion criteria

Exclusion Criteria:

  • Current respiratory tract disorder other than
  • history of asthma or rhinitis
  • significant or unstable cardiovascular disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    Symbicort then Formoterol then Placebo

    Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily

    Drug: budesonide/formoterol Turbuhaler 320/9µg · Drug: formoterol Turbuhaler 9µg · Other: Placebo

  • Experimental
    Formoterol then Symbicort then Placebo

    Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily

    Drug: budesonide/formoterol Turbuhaler 320/9µg · Drug: formoterol Turbuhaler 9µg · Other: Placebo

  • Placebo comparator
    Placebo then Formoterol then Symbicort

    Placebo, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily

    Drug: budesonide/formoterol Turbuhaler 320/9µg · Drug: formoterol Turbuhaler 9µg · Other: Placebo

Interventions

  • Drugbudesonide/formoterol Turbuhaler 320/9µg

    Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms

  • Drugformoterol Turbuhaler 9µg

    Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily

  • OtherPlacebo

    Placebo, 1 inhalation twice daily

06

What researchers measure

Primary outcomes

  1. Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 1 Hour Post-dose

    Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.

    Time frame: Single measurement taken1 hour post-dose at the end of each 1-week treatment period

Secondary outcomes

  1. Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 6 Hour Post-dose

    Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.

    Time frame: Single measurement taken 6 hours post-dose at the end of each 1-week treatment period

  2. Forced Expiratory Flow (FEV1) Pre-dose

    The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.

    Time frame: Pre-dose at the start of treatment and pre-dose after one week of treatment

  3. Forced Vital Capacity (FVC) Pre-dose

    The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.

    Time frame: Pre-dose at the start of treatment and pre-dose after one week of treatment

  4. Vital Capacity (VC) Pre-dose (Change From Pre-treatment to Treatment)

    The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.

    Time frame: Pre-dose at the start of treatment and pre-dose after one week of treatment

  5. Peak Expiratory Flow (PEF) Before Morning Dose

    The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period.

    Time frame: Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period

  6. Sleep Score

    The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (symptoms did not cause a sleep problem) to 4 (did not sleep at all due to symptoms).

    Time frame: Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period

  7. Breathlessness Score

    The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any difficulty in breathing) to 4 (almost constant difficulties in breathing). All patients with data from both periods are included.

    Time frame: Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period

  8. Chest Tightness Score

    The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any discomfort) to 4 (almost constant discomfort).

    Time frame: Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period

  9. Cough Score

    The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of coughing) to 4 (never free of need to cough).

    Time frame: Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period

  10. Number of Inhalations of Reliever Medication

    The change in average daily use for the run-in or wash-out period to the average daily use of the subsequent treatment period.

    Time frame: Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period

  11. Borg CR10 Score Before Exercise Endurance Time (EET) Performed 1 Hour Post-dose

    The Borg CR10 Scale consists of 10-point score that the patients pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness. Patients are allowed to assign an even higher number depending on their perceived level of breathlessness).

    Time frame: Single measurement performed at rest prior to exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period

  12. Borg CR10 Score After Exercise Endurance Time (EET) Performed 1 Hour Post-dose

    The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to \>10 (absolute maximum breathing discomfort).

    Time frame: Single measurement performed after exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period

  13. Borg CR10 Score Before Exercise Endurance Time (EET) Performed 6 Hour Post-dose

    The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to \>10 (absolute maximum breathing discomfort).

    Time frame: Single measurement performed at rest prior to exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period

  14. Borg CR10 Score After Exercise Endurance Time (EET) Performed 6 Hours Post-dose

    The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to \>10 (absolute maximum breathing discomfort). All patients with data are included.

    Time frame: Single measurement performed after exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period

  15. Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 1 Hour Postdose

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period

  16. Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 6 Hours Post-dose

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period

  17. Vital Capacity (VC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period

  18. Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 1hour post-dose at the end of each 1-week treatment period

  19. Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period

  20. Residual Volume (RV) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period

  21. Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period

  22. Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period

  23. Vital Capacity (VC) (Body Plethysmography) Performed Before 6 Hour Exercise Endurance Time (EET)

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period

  24. Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period

  25. Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period

  26. Residual Volume (RV) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 6 hous post-dose at the end of each 1-week treatment period

  27. Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period

  28. Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 6 Hours Post-dose EET

    Treatment means from individual participant data.

    Time frame: Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period

  29. SGRQ-C (St. George's Respiratory Questionnaire for COPD Patients) Total Score

    Score from a questionnaire, with scores ranging form 0 (perfect health) to 100 (worst possible state). Includes all patients with data.

    Time frame: Single measurement taken at the end of each 1-week treatment period

07

Results

Posted Aug 30, 2012

Participant flow

Patients were recruited in 12 centers in Germany and 12 centers in Switzerland.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneSymbicort Then Formoterol Then PlaceboFormoterol Then Symbicort Then PlaceboPlacebo Then Formoterol Then Symbicort
Started363738
Completed363738
Not completed000
Wash-out Period 1
Participant flow — Wash-out Period 1
MilestoneSymbicort Then Formoterol Then PlaceboFormoterol Then Symbicort Then PlaceboPlacebo Then Formoterol Then Symbicort
Started363738
Completed353432
Not completed136
Withdrew: Withdrawal by subject100
Withdrew: Adverse event011
Withdrew: Protocol violation011
Withdrew: Study-specific discontinuation criteria014
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneSymbicort Then Formoterol Then PlaceboFormoterol Then Symbicort Then PlaceboPlacebo Then Formoterol Then Symbicort
Started333533
Completed333533
Not completed000
Wash-out Period 2
Participant flow — Wash-out Period 2
MilestoneSymbicort Then Formoterol Then PlaceboFormoterol Then Symbicort Then PlaceboPlacebo Then Formoterol Then Symbicort
Started333533
Completed293231
Not completed432
Withdrew: Adverse event110
Withdrew: Study specific discontinuation criteria322
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneSymbicort Then Formoterol Then PlaceboFormoterol Then Symbicort Then PlaceboPlacebo Then Formoterol Then Symbicort
Started293033
Completed292933
Not completed010
Withdrew: Study specific discontinuation criteria010
Follow-up Period
Participant flow — Follow-up Period
MilestoneSymbicort Then Formoterol Then PlaceboFormoterol Then Symbicort Then PlaceboPlacebo Then Formoterol Then Symbicort
Started292933
Completed292933
Not completed000

Outcome measures

PrimaryExercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 1 Hour Post-dose

Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.

Time frame:
Single measurement taken1 hour post-dose at the end of each 1-week treatment period
Reported as:
Mean · Seconds
Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 1 Hour Post-dose
SecondsSymbicortFormoterolPlacebo
Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 1 Hour Post-dose529 ± 377441 ± 292406 ± 306
SecondaryExercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 6 Hour Post-dose

Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.

Time frame:
Single measurement taken 6 hours post-dose at the end of each 1-week treatment period
Reported as:
Mean · Seconds
Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 6 Hour Post-dose
SecondsSymbicortFormoterolPlacebo
Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 6 Hour Post-dose463 ± 312408 ± 283388 ± 306
SecondaryForced Expiratory Flow (FEV1) Pre-dose

The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.

Time frame:
Pre-dose at the start of treatment and pre-dose after one week of treatment
Reported as:
Mean · Liters
Forced Expiratory Flow (FEV1) Pre-dose
LitersSymbicortFormoterolPlacebo
Forced Expiratory Flow (FEV1) Pre-dose0.0830 ± 0.24800.0630 ± 0.2500-0.046 ± 0.1830
SecondaryForced Vital Capacity (FVC) Pre-dose

The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.

Time frame:
Pre-dose at the start of treatment and pre-dose after one week of treatment
Reported as:
Mean · Liters
Forced Vital Capacity (FVC) Pre-dose
LitersSymbicortFormoterolPlacebo
Forced Vital Capacity (FVC) Pre-dose0.060 ± 0.4060.067 ± 0.407-0.094 ± 0.360
SecondaryVital Capacity (VC) Pre-dose (Change From Pre-treatment to Treatment)

The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.

Time frame:
Pre-dose at the start of treatment and pre-dose after one week of treatment
Reported as:
Mean · Liters
Vital Capacity (VC) Pre-dose (Change From Pre-treatment to Treatment)
LitersSymbicortFormoterolPlacebo
Vital Capacity (VC) Pre-dose (Change From Pre-treatment to Treatment)0.105 ± 0.36000.089 ± 0.370-0.083 ± 0.371
SecondaryPeak Expiratory Flow (PEF) Before Morning Dose

The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period.

Time frame:
Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period
Reported as:
Mean · Liters/minute
Peak Expiratory Flow (PEF) Before Morning Dose
Liters/minuteSymbicortFormoterolPlacebo
Peak Expiratory Flow (PEF) Before Morning Dose1.30 ± 32.705.60 ± 21.50-10.00 ± 27.00
SecondarySleep Score

The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (symptoms did not cause a sleep problem) to 4 (did not sleep at all due to symptoms).

Time frame:
Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period
Reported as:
Mean · Score on Scale
Sleep Score
Score on ScaleSymbicortFormoterolPlacebo
Sleep Score-1.70 ± 0.47-0.03 ± 0.470.11 ± 0.47
SecondaryBreathlessness Score

The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any difficulty in breathing) to 4 (almost constant difficulties in breathing). All patients with data from both periods are included.

Time frame:
Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period
Reported as:
Mean · Score on Scale
Breathlessness Score
Score on ScaleSymbicortFormoterolPlacebo
Breathlessness Score-0.12 ± 0.54-0.40 ± 0.460.15 ± 0.49
SecondaryChest Tightness Score

The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any discomfort) to 4 (almost constant discomfort).

Time frame:
Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period
Reported as:
Mean · Score on a scale
Chest Tightness Score
Score on a scaleSymbicortFormoterolPlacebo
Chest Tightness Score-0.08 ± 0.46-0.02 ± 0.470.17 ± 0.47
SecondaryCough Score

The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of coughing) to 4 (never free of need to cough).

Time frame:
Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period
Reported as:
Mean · Scores on a scale
Cough Score
Scores on a scaleSymbicortFormoterolPlacebo
Cough Score-0.11 ± 0.51-0.05 ± 0.500.10 ± 0.45
SecondaryNumber of Inhalations of Reliever Medication

The change in average daily use for the run-in or wash-out period to the average daily use of the subsequent treatment period.

Time frame:
Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period
Reported as:
Mean · Number of inhalations during 24 hours
Number of Inhalations of Reliever Medication
Number of inhalations during 24 hoursSymbicortFormoterolPlacebo
Number of Inhalations of Reliever Medication-0.42 ± 1.51-0.36 ± 1.260.51 ± 1.33
SecondaryBorg CR10 Score Before Exercise Endurance Time (EET) Performed 1 Hour Post-dose

The Borg CR10 Scale consists of 10-point score that the patients pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness. Patients are allowed to assign an even higher number depending on their perceived level of breathlessness).

Time frame:
Single measurement performed at rest prior to exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Reported as:
Mean · Scores on a scale
Borg CR10 Score Before Exercise Endurance Time (EET) Performed 1 Hour Post-dose
Scores on a scaleSymbicortFormoterolPlacebo
Borg CR10 Score Before Exercise Endurance Time (EET) Performed 1 Hour Post-dose3.3 ± 3.23.4 ± 3.13.9 ± 3.5
SecondaryBorg CR10 Score After Exercise Endurance Time (EET) Performed 1 Hour Post-dose

The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to \>10 (absolute maximum breathing discomfort).

Time frame:
Single measurement performed after exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Reported as:
Mean · Scores on a scale
Borg CR10 Score After Exercise Endurance Time (EET) Performed 1 Hour Post-dose
Scores on a scaleSymbicortFormoterolPlacebo
Borg CR10 Score After Exercise Endurance Time (EET) Performed 1 Hour Post-dose11.5 ± 2.711.6 ± 2.911.4 ± 2.9
SecondaryBorg CR10 Score Before Exercise Endurance Time (EET) Performed 6 Hour Post-dose

The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to \>10 (absolute maximum breathing discomfort).

Time frame:
Single measurement performed at rest prior to exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Reported as:
Mean · Scores on a scale
Borg CR10 Score Before Exercise Endurance Time (EET) Performed 6 Hour Post-dose
Scores on a scaleSymbicortFormoterolPlacebo
Borg CR10 Score Before Exercise Endurance Time (EET) Performed 6 Hour Post-dose3.6 ± 3.23.4 ± 3.13.9 ± 3.5
SecondaryBorg CR10 Score After Exercise Endurance Time (EET) Performed 6 Hours Post-dose

The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to \>10 (absolute maximum breathing discomfort). All patients with data are included.

Time frame:
Single measurement performed after exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Reported as:
Mean · Scores on a scale
Borg CR10 Score After Exercise Endurance Time (EET) Performed 6 Hours Post-dose
Scores on a scaleSymbicortFormoterolPlacebo
Borg CR10 Score After Exercise Endurance Time (EET) Performed 6 Hours Post-dose11.5 ± 2.911.5 ± 3.111.8 ± 3.1
SecondaryInspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 1 Hour Postdose

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Reported as:
Mean · Liter
Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 1 Hour Postdose
LiterSymbicortFormoterolPlacebo
Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 1 Hour Postdose2.06 ± 0.852.10 ± 0.821.97 ± 0.72
SecondaryInspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 6 Hours Post-dose

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Reported as:
Mean · Liters
Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 6 Hours Post-dose
LitersSymbicortFormoterolPlacebo
Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 6 Hours Post-dose2.12 ± 0.792.12 ± 0.801.85 ± 0.84
SecondaryVital Capacity (VC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Reported as:
Mean · Liters
Vital Capacity (VC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)
LitersSymbicortFormoterolPlacebo
Vital Capacity (VC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)2.75 ± 0.722.73 ± 0.772.37 ± 0.66
SecondaryInspiratory Capacity (IC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 1hour post-dose at the end of each 1-week treatment period
Reported as:
Mean · Liters
Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)
LitersSymbicortFormoterolPlacebo
Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)2.19 ± 0.612.18 ± 0.701.91 ± 0.58
SecondaryForced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Reported as:
Median · Liters
Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)
LitersSymbicortFormoterolPlacebo
Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)5.59 ± 1.695.66 ± 1.615.79 ± 1.64
SecondaryResidual Volume (RV) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Reported as:
Mean · Liters
Residual Volume (RV) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)
LitersSymbicortFormoterolPlacebo
Residual Volume (RV) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)4.83 ± 1.594.94 ± 1.625.13 ± 1.65
SecondaryTotal Lung Capacity (TLC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Reported as:
Mean · Liter
Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)
LiterSymbicortFormoterolPlacebo
Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)7.58 ± 1.717.62 ± 1.687.45 ± 1.76
SecondarySpecific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Reported as:
Mean · kilopascal
Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)
kilopascalSymbicortFormoterolPlacebo
Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)2.90 ± 1.662.98 ± 1.814.22 ± 2.29
SecondaryVital Capacity (VC) (Body Plethysmography) Performed Before 6 Hour Exercise Endurance Time (EET)

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Reported as:
Mean · Liters
Vital Capacity (VC) (Body Plethysmography) Performed Before 6 Hour Exercise Endurance Time (EET)
LitersSymbicortFormoterolPlacebo
Vital Capacity (VC) (Body Plethysmography) Performed Before 6 Hour Exercise Endurance Time (EET)2.69 ± 0.7302.64 ± 0.782.42 ± 0.71
SecondaryInspiratory Capacity (IC) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Reported as:
Mean · Liters
Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)
LitersSymbicortFormoterolPlacebo
Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)2.14 ± 0.602.08 ± 0.691.92 ± 0.66
SecondaryForced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Reported as:
Mean · Liters
Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)
LitersSymbicortFormoterolPlacebo
Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)5.47 ± 1.655.49 ± 1.455.82 ± 1.88
SecondaryResidual Volume (RV) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 6 hous post-dose at the end of each 1-week treatment period
Reported as:
Mean · Liters
Residual Volume (RV) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)
LitersSymbicortFormoterolPlacebo
Residual Volume (RV) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)4.74 ± 1.634.79 ± 1.525.19 ± 1.92
SecondaryTotal Lung Capacity (TLC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Reported as:
Mean · Liters
Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)
LitersSymbicortFormoterolPlacebo
Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)7.41 ± 1.687.37 ± 1.557.63 ± 2.00
SecondarySpecific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 6 Hours Post-dose EET

Treatment means from individual participant data.

Time frame:
Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Reported as:
Mean · Kilopascals
Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 6 Hours Post-dose EET
KilopascalsSymbicortFormoterolPlacebo
Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 6 Hours Post-dose EET3.06 ± 1.683.20 ± 2.024.12 ± 2.54
SecondarySGRQ-C (St. George's Respiratory Questionnaire for COPD Patients) Total Score

Score from a questionnaire, with scores ranging form 0 (perfect health) to 100 (worst possible state). Includes all patients with data.

Time frame:
Single measurement taken at the end of each 1-week treatment period
Reported as:
Mean · Scores on a scale
SGRQ-C (St. George's Respiratory Questionnaire for COPD Patients) Total Score
Scores on a scaleSymbicortFormoterolPlacebo
SGRQ-C (St. George's Respiratory Questionnaire for COPD Patients) Total Score51.7 ± 1851.6 ± 19.254.5 ± 18.9

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Symbicort—2/101 (2%)4/101 (4%)
Formoterol—1/102 (1%)3/102 (2.9%)
Placebo—1/104 (1%)6/104 (5.8%)
Most frequent serious events
Most frequent serious events
EventSymbicortFormoterolPlacebo
Wrist FractureInjury, poisoning and procedural complications1/1010/1020/104
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders1/1011/1021/104
Most frequent other events
Most frequent other events
EventSymbicortFormoterolPlacebo
Chonic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders4/1013/1026/104

Baseline characteristics

Age Continuous
Age Continuous(Year)Entire Study Population
Mean63.7 (42 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female27
Male84
08

Study locations

9 sites
  • Research Site
    Berlin, Germany
  • Research Site
    Erfurt, Germany
  • Research Site
    Fulda, Germany
  • Research Site
    Furth, Germany
  • Research Site
    Geesthacht, Germany
  • Research Site
    Grobhansdorf, Germany
  • Research Site
    Leipzig, Germany
  • Research Site
    Neuruppin, Germany
  • Research Site
    Basel, Basel Stadt, Switzerland
09

References and documents

Publications

  • Worth H, Forster K, Eriksson G, Nihlen U, Peterson S, Magnussen H. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med. 2010 Oct;104(10):1450-9. doi: 10.1016/j.rmed.2010.07.006. Epub 2010 Aug 7. PubMed 20692140 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2007
First posted
Jun 21, 2007
Start
Jul 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Aug 30, 2012
Last update
Aug 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00489853
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 21, 2007
Start date
Jul 2007
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Aug 30, 2012
Last update
Aug 30, 2012

Study contacts

Tomas Andersson, MD
study director · AstraZeneca
Heinrich Worth, MD
principal investigator · Akademisches Lehrkrankenhaus der Universität Erlangen-Nürnberg, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion